» Articles » PMID: 38404940

Evidence That Inositol 1,4,5-trisphosphate 3-kinase and Inositol 1,3,4,5-tetrakisphosphate Are Negative Regulators of Platelet Function

Overview
Publisher Elsevier
Date 2024 Feb 26
PMID 38404940
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Inositol 1,3,4,5-tetrakisphosphate (IP) is formed from inositol 1,4,5-trisphosphate (IP) by IP 3-kinase (ITPK) in most cells. Its function is unknown but has been suggested to be involved in Ca entry, IP regulation, and phosphoinositide 3-kinase antagonism.

Objectives: To better elucidate a function for IP, we tested a specific inhibitor of ITPK (GNF362) on platelets, the effects of IP directly in permeabilized platelets and its effect on phosphatidylinositol 3,4,5-trisphosphate (PIP) binding to pleckstrin-homology (PH) domain-containing proteins in platelets.

Methods: Human platelets were utilized in whole blood for thrombus formation, in platelet-rich plasma and washed suspensions for aggregation, and for Ca studies, or resuspended in high K and low Na buffers for permeabilization experiments. Phosphorylation of AKT-Ser and Rap1-GTP formation were measured by Western blotting and PIP binding using PIP beads.

Results: GNF362-enhanced platelet aggregation stimulated by low concentrations of ADP, collagen, thrombin, U46619, and thrombus formation in collagen-coated capillaries. GNF362 induced a transient elevation of Ca concentration, elevated basal levels of IP, and enhanced the peak height of Ca elevated by agonists. In permeabilized platelets, IP inhibited GTPγS induced formation of AKT-Ser phosphorylation and platelet aggregation. IP reduced GTPγS-stimulated Rap1-GTP levels and potently reduced extraction of RASA3 and BTK by PIP beads.

Conclusion: ITPK and IP are negative regulators of platelet function. IP regulation of PH domain-containing proteins may represent a pathway by which platelet activation may be controlled during thrombosis.

Citing Articles

Inositol 1,3,4,5-tetrakisphosphate: a remarkable second messenger in platelet signaling.

Mammadova-Bach E, Braun A Res Pract Thromb Haemost. 2024; 8(2):102365.

PMID: 38550530 PMC: 10973178. DOI: 10.1016/j.rpth.2024.102365.

References
1.
Miller A, Dahlberg C, Sandberg M, Wen B, Beisner D, Hoerter J . Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease. PLoS One. 2015; 10(6):e0131071. PMC: 4488288. DOI: 10.1371/journal.pone.0131071. View

2.
Jia Y, Subramanian K, Erneux C, Pouillon V, Hattori H, Jo H . Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5- trisphosphate signaling in neutrophils. Immunity. 2007; 27(3):453-67. PMC: 2084373. DOI: 10.1016/j.immuni.2007.07.016. View

3.
Authi K, Evenden B, Crawford N . Metabolic and functional consequences of introducing inositol 1,4,5-trisphosphate into saponin-permeabilized human platelets. Biochem J. 1986; 233(3):707-18. PMC: 1153089. DOI: 10.1042/bj2330707. View

4.
Stefanini L, Lee R, Paul D, OShaughnessy E, Ghalloussi D, Jones C . Functional redundancy between RAP1 isoforms in murine platelet production and function. Blood. 2018; 132(18):1951-1962. PMC: 6213319. DOI: 10.1182/blood-2018-03-838714. View

5.
Authi K . Orai1: a channel to safer antithrombotic therapy. Blood. 2009; 113(9):1872-3. DOI: 10.1182/blood-2008-11-185959. View